This site is intended for healthcare professionals
News

Kisqali + endocrine therapy demonstrates nearly five years median overall survival in metastatic HER2- breast cancer.- Novartis

Read time: 1 mins
Last updated:10th Dec 2020
Published:10th Dec 2020
Condition: Breast Cancer HER2-
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest